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PROFORMA 
Date: 
Name of the patient: 
Age/Sex: 
Address: 
Glaucoma clinic registration number: 
 
HISTORY 
Complaints: 
H/O Defective vision: 
H/O Pain, halos or redness: 
H/O trauma: 
H/O prior ocular surgeries or Yag PI: 
H/O other medical illnesses and medications: 
Family H/O glaucoma: 
 
EXAMINATION 
Visual acuity: 
Intra-ocular pressure (NCT): 
Intra-ocular pressure (Goldmann Applanation): 
Central corneal thickness: 
Gonioscopy: 
Cup: Disc ratio: 
Automated perimetry (Loss variance): 
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RNFL thickness by OCT: 
 
DIAGNOSIS: 
 
MEDICATIONS: 
 
SURGERY DONE: 
 
FOLLOW-UP: 
Visual acuity: 
Intra-ocular pressure (NCT): 
Intra-ocular pressure (Goldmann Applanation): 
Central corneal thickness: 
Gonioscopy: 
Cup: Disc ratio: 
Automated perimetry (Loss variance): 
RNFL thickness by OCT: 
Complications (if any): 
Additional therapy (if any): 
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KEY TO MASTER CHART 
 
DIA  - Diagnosis 
IOP  - Intraocular Pressure 
CT  - Central Corneal Thickness 
CD  - Cup: Disc ratio 
LV  - Loss Variance by Automated Perimetry 
RNFL  - Retinal Nerve Fibre Layer Thickness by OCT 
POAG  - Primary Open Angle Glaucoma 
PACG  - Primary Angle Closure Glaucoma 
CG  - Congenital Glaucoma 
JG  - Juvenile Glaucoma 
AG  - Trabeculectomy surgery 
AG & O - Trabeculectomy surgery with the OloGen implant 
MT   - Medical Therapy 
MMT  - Maximum Medical Therapy 
RE TR  - Repeat Trabeculectomy 
MTF  - Micro Track filtration with the Fugo blade 
REV  - Revision of the bleb 
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ABBREVIATIONS 
 
POAG  - Primary Open Angle Glaucoma 
PACG  - Primary Angle Closure Glaucoma 
IOP  - Intraocular Pressure 
GAT  - Goldmann Applanation Tonometry 
CCT  - Central corneal Thickness 
AP  - Octopus Automated Perimetry 
LV  - Loss Variance 
RNFL  - Retinal Nerve Fiber Layer thickness 
OCT  - Optical Coherence Tomography 
ONH  - Optic Nerve Head 
C:D  - Cup : Disc ratio 
NRR  - Neuro Retinal Rim 
AGIS  - Advanced Glaucoma Intervention Study 
EMGT  - Early Manifest Glaucoma Trial 
CNTGS - Collaborative Normal Tension Glaucoma Study 
MMC  - Mitomycin C 
5FU  - 5 Fluorouracil 
GDD  - Glaucoma Drainage Devices 
PI  - Peripheral Iridotomy 
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INTRODUCTION 
 
Glaucoma is a leading cause of irreversible blindness throughout the world. The 
modern understanding of the disease dates back to the mid- 19th century. However, 
this disease was recognised by the Greeks and Hippocrates refers to the entity as 
“glaucosis”. World Health Organisation statistics indicate that glaucoma accounts for 
13.5% of global blindness (5.1 million persons). 
 
Glaucoma is not a single disease process but a large group of disorders with a 
common denominator of a characteristic optic neuropathy. Although elevated intra-
ocular pressure (IOP) is the most frequent risk factor for glaucomatous optic atrophy, 
it is not the only factor and attempts to classify glaucoma on the basis of ocular 
tension are no longer valid. Nevertheless, the IOP remains a crucial parameter to the 
clinician as along with the aqueous dynamics, it is the only factor that can be 
controlled to prevent progressive optic neuropathy. 
 
Blindness caused by glaucoma is irreversible. In nearly all cases, however, it is 
preventable. This requires early detection and management. There are a multitude of 
clinical and instrumental investigations available to help in the diagnosis of glaucoma. 
A clinician needs to have a thorough understanding of the disease process in order to 
successfully diagnose and treat the disease. 
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REVIEW OF LITERATURE 
 
ANATOMY OF THE ANTERIOR CHAMBER ANGLE AND CILIARY BODY 
 
I. Schwalbe's Line: 
 
Schwalbe’s line (composed of collagen and elastic tissue) is an irregular elevation 50–
150 microns wide that runs circumferentially around the globe1. This line or zone 
marks the transition from endothelium of the trabecular meshwork to the corneal 
endothelium. It is marked internally by the Descemet’s membrane termination. 
Secretory cells, called Schwalbe’s line cells, are present in this area that produce a 
phospholipid material thought to facilitate aqueous flow2,3. 
 
The Schwalbe’s line can be subdivided based on the histology. The anterior border 
adjacent to the cornea is a zone of transformation from trabecular meshwork to 
corneal endothelium. 
 
The posterior border is an elevation formed due to the insertion of uveal part of 
trabecular tissue into the limbal stroma 
 
II. Trabecular Meshwork 
 
The trabeculum is a three dimensional structure. It has criss-crossing collagen fibres 
within the scleral canal which creates a circular channel known in ophthalmic 
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parlance as the Schlemm's canal. It is constituted by a connective tissue centre 
surrounded by endothelium. This segment can further be studied histologically. It has 
few subdivisions: 
 
a. The uveal meshwork lies adjacent to the anterior chamber. It is composed of 
trabecular bands. These bands vary in size of openings. The openings range 
from 25 to 75 microns. They extend from the root of the iris and ciliary body 
to the anteriorly placed Schwalbe's line. 
 
b. The corneoscleral meshwork is constituted by similar plates of trabecular 
tissue with ovoid pores in the range of 5 to 50 microns in diameter bridging 
the scleral spur to the front of the scleral sulcus 
 
c. The juxtacanalicular connective tissue is composed of the outermost portion of 
the system. It is made up of connective tissue interior bordered on either side 
by endothelium. The outer endothelium is continuous with the interior side of 
Schlemm's canal thus forming the major site of resistance to aqueous outflow 
from the eye. The transcellular transport of aqueous has a system composed of 
pores and with vacuoles which establish a communication between the 
Schlemm's canal. 
 
III. Schlemm's canal 
  
The Schlemm’s canal is an endothelium lined channel like structure which is 195 to 
375 micrometer in size4. Changes in aqueous outflow from the eye which are 
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dependent on gradient changes in the pressure between the anterior chamber and the 
schlemm’s canal might occur. It is likely due to an increased resistance to the outflow 
of aqueous accompanied by increase in intraocular pressure which causes canal 
collapse. 
 
IV. Scleral spur 
 
The posterior border of the scleral sulcus is is an elevated whitish structure. It is 
formed by the sclera and insertion of the longitudinal portion of the ciliary muscle. 
This is composed of collagen fibers. 
 
V. The  Ciliary body band 
 
This discrete structure is dark coloured and extends 5 mm posteriorly from the scleral 
spur  to the insertion of the retina and choroid at the ora serrata in the posterior 
segment5. It is primarily composed of muscular tissue. Other components are blood 
vessels and the  epithelium. This structure which forms a band presents the part of 
ciliary body visible on gonioscopic examination. The width of the ciliary body 
indicates the of the iris insertion level. Approach of iris to this band may be convex or 
concave. On some occasions, plateau or flat insertions may be encountered. 
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This ciliary body band is subdivided as follows into various parts 
 
I. THE PARS PLICATA – It is formed by anterior 2 to 3 mm of the ciliary body. Its 
constituents are : 
 
1.The Ciliary muscle: 
− Longitudinally oriented fibers insert into the scleral spur in front. They 
provide an attachment for the ciliary body at the limbus. They also provide 
attachment to suprachoroidal lamina behind and extnd upto the equator of the 
eye. Hence an effect on aqueous outflow can be demonstrated when themuscle 
acts 
 
− Circularly oriented fibers are present in the anterior portion of the muscle and 
are placed parallel to the limbal region. They play a role in accommodation 
 
− Radially oriented fibers connect the aforementioned parts of the ciliary 
muscular apparatus. 
 
2. Ciliary vessels: 
− The anterior ciliary artery and long posterior ciliary arteries (2 in number) 
form an anastomosis close to the root of iris. These together constitute the 
major arterial circle. 
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− The supply extends to iris, entire ciliary body region and choroidal layer. They 
can be injured by iridodialysis and lead to hyphema.  
 
− Venous outflow is through  vortex veins and intrascleral plexus. The episcleral 
veinous channels play a minor role. 
 
3. Ciliary processes: 
− The pars plicata is thrown into 75 to 85 folds. Zonular fibers find attachment 
in the troughs formed by these ciliary processes. Few attachments are also to 
the pars plana. The ciliary processes have these layers: 
 
− A. The Ciliary epithelium which is composed of two types of epithelial layers. 
Pigmented epithelial layer forms the outer zone. It is nearer to the stroma and 
consists of cuboidal cells. A prominent nucleus and melanosome granules are 
seen. The nonpigmented inner epithelium layer in contact with aqueous is 
made up of columnar cells which transform to cuboid shape in the pars plana 
region. Tight junctions known as the zonulae occludens constitute the blood 
aqueous barrier. The apices of nonpigmented epithelium are the sites of active 
aqueous secretion. Thus this region has many mitochondrion, endoplasmic 
reticulum and vesicles. Enzymes like the NaK ATPase & carbonic anhydrase 
are also predominant. 
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− B. A capillary network constitutes the center of each ciliary process. The 
major arterial circle supplies these capillaries. The endothelium of these 
vessels is fenestrated. Thus maximal permeability is allowed in this network. 
 
− C. The stromal region is composed of a mucopolysaccharide base. Further, 
collagen fibers separate the capillaries from the epithelium. They constitute 
the main mass of the ciliary body. 
 
II. THE PARS PLANA REGION –  It is composed of the posterior 3 to 4.5 millimeters 
of ciliary body6. It bridges the choroid with ora serrata. Similar to the pars plicata, 
pigmented and non-pigmented epithelium is encountered here. The non-pigmented 
epithelium is the site of production of vitreous mucopolysaccharides. 
 
GONIOSCOPY: 
Visualisation of the anterior chamber angle and structures contained therein is termed 
Gonioscopy2. It can be diagnostic or therapeutic.  
One cannot see the angle structure directly due to total internal reflection. This 
physical phenomenon occurs at the cornea to air interface.  The critical angle for this 
interface  is  47o. Instruments which aid in this procedure are the Goniolenses. They 
have a refractive index similar to the cornea. Hence, the optical effect of total internal 
reflection is removed from the system. 
Light emanating from the cornea is seen by two basic mechanisms which form the 
basis of the types of goniolenses: 
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− Direct gonioscopic examination needs the patient to be supine. Refraction of 
rays at the lens to air interface occurs. The examiner needs a light from outside 
to aid the visualisation. A few examples are the Koeppe, Swan Jacob, Thorpe 
and Barkan lenses. 
 
− Indirect gonioscopic examination can be performed with the patient sitting. 
Here light rays coming from the chamber angle are reflected. The instrument 
uses a mirror for this purpose. Examples are the Goldmann mirrors and Zeiss 
gonioscopes. Some instruments are known as indentation gonioprisms. They 
enable distinction between appositional and synechial closure of the angle. 
Examples are the Zeiss and Posner lenses. 
 
OPTIC NERVE HEAD ANATOMY 
 
The optic nerve is the second cranial nerve. It is constituted by 1.2 to 1.3 million 
axons7. The axonal processes are derived from the cell bodies of the retinal ganglion 
cells. The RGC axons from all parts of the retina converge upon the optic nerve head. 
On the optic nerve head surface, axons of RGCs take a sharp turn and leave the globe 
by passing through the fenestrated lamina cribrosa formed by the sclera2,3. These 
axons constitute the visual pathway. They lead on to the optic nerve and chiasm. From 
there, optic tract runs backward and synapses at the lateral geniculate body which is a 
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part of the thalamus. Further course of the visual pathway is via the optic radiation 
and finally terminates at the cortex of the occipital lobe. 
 
The term “optic nerve head” (ONH) refers to the distal part of the optic nerve which is 
ovoid in orientation. The structure has a three dimensional orientation. The extent can 
be traced from surface of the retina to the sclera lamina cribrosa. The ONH is the site 
where RGC axons leave the eye. It is seen 3.5 – 4.5 mm nasal to the fovea. The main 
constituents are  neural tissue elements, collagen support and few blood vessels in the 
substance. The ONH is 1.5 millimeter in width. It is normal to observe a large 
variation in this size within a normal population. The central part of ONH has a small 
depression. It is referred to as the optic cup. It  represents a portion of the ONH with 
relative paucity of axons. The neural elements between the cup marin and the disc is 
known as the neuroretinal rim (NRR). 
 
Degeneration of the axons of the NRR is seen as thinning of the rim and characterises 
the various changes seen in glaucomatous optic atrophy. These changes in the neural 
rim of glaucoma affected eyes cause optic cup enlargement with subsequent field loss. 
The cup : disc ratio (C/D) an indicator of NRR. This could be erroneous when the 
bigger nerve head may contain an enlarged cup. There could also be a decreased NRR 
width inspite of a normal of neural tissue on the ONH. The NRR is characteristically 
broad over the inferior sector of the disc. This is followed by the superior NRR and 
the nasal side. The temporal side if the disc has the thinnest NRR. This typical 
arrangement is often referred to as the ISNT rule. 
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Various studies that employed stereoscopy have shown a mean c:d of 0.4 in very few 
eyes (around 5%). However, a 0.7 disc or larger or a c:d difference of more than 0.2 
between two eyes occured only in 2% of the normal population. The size of the cups 
may be a manifestation of multifactorial patterns of heredity.  Studies also show a 
larger disc and C/D in black patients. This is important as glaucomatous optic atrophy 
shows a progressive and asymmetric loss of NRR. 
 
There are no photoreceptors on the ONH. Hence it corresponds to a blind spot in the 
visual field. The size is a 5.5 to 7.5 degree scotoma. This is known as the blind spot of 
Mariotte and is located temporal visual field. 
 
Subdivisions of the ONH: 
− The nerve fiber layer (NFL): The retinal nerves enter the optic nerve in a 
particular pattern. This pattern is responsible for the various nerve fiber layer 
and consequent field defects. The retinal nerve fibers originating in the 
temporal retina arise on both sides of a horizontally oriented line. This is 
known as the median raphe. Fibers then arch superior and inferior to the fovea 
in an arcuate manner and are called the arcuate fibers. Arcuate nerve fibers 
which enter the superior and inferior poles of the ONH are more susceptible to 
damage in glaucoma. The papillomacular fibers from the fovea and fibers 
from nasal retina take a more direct route to the optic NH. All these retinal 
fibers are visible ophthalmoscopically as striations over the retina around the 
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ONH. The RNFL is primarily supported by the retinal astrocytes. It receives a 
vascular supply from the central retinal artery. 
 
− The Prelaminar portion of the ONH: This part is clinically visible as a central 
depression called the optic cup and contains axons and glial supporting 
elements. Blood supply originates from the short posterior ciliary  system of 
vessels. Minor branches from the surrounding choroid are also seen. 
 
− The lamina cribrosa: Deep to the prelaminar part, fenestrated sheets of sclera 
are arranged in around 15 plate like structures with about 500 to 700 pores 
which permit bundles of neuronal elements to leave the ONH. Blood supply is 
from the short posterior ciliary system of vessels that form the arterial circle of 
Zinn. 
 
− The retrolaminar region: The part of the ONH which lies posterior to the 
lamina cribrosa is the retrolaminar region. It is primarily extra ocular. It is 
characterized by the myelinisation of axons that exit the lamina cribrosa. The 
myelin of the nerve is produced by oligodendrocytes. Thereafter, the diameter 
of the nerve increases to double its size. Blood supply is from the branches of 
the meningeal artey and the central retinal artery. Hence the retrolaminar 
region receives supply from both ciliary system and retinal circulations. 
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AQUEOUS HUMOR DYNAMICS 
 
Intraocular pressure maintenance and thus the study of the pathology of glaucoma is 
dependent on the aqueous humor and its dynamics. Aqueous is primarily derived from 
the blood plasma8.  Plasma from within the ciliary process capillary network is 
converted to the aqueous of the anterior chamber by three distint physiologic 
processes: 
 
1. Diffusion- The lipid soluble substances diffuse through the lipid constituted 
parts of the ciliary process cell membrane. The rate at which the process 
occurs is dependent on the concentration gradient of the same substance on 
both sides of the membrane. 
 
2. Ultrafiltration – Apart from diffusion, the addition of water and water soluble 
substances to the aqueous by this process. It is dependent on size of the 
substance and its charge. Flow in one direction via small pores in the 
membrane of the cell occurs secondary to an osmotic gradient. The hydrostatic 
pressure across the barrier also plays a role. Some other factors are intraocular 
pressure, ciliary capillary blood pressure and oncotic pressure of the plasma. 
These are passive transport mechanisms and limited by the presence of tight 
junctions between the nonpigmented ciliary epitheliaum. 
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3. Active transport: This process is also termed secretion. Larger substances 
which are water soluble and with more charge are transported by this 
modality. It is an active process and needs energy. NaK ATPase enzyme and 
enzymes of glycolysis are seen in the nonpigmented epitheliaum. They bring 
about active secretion. It is decreased in hypoxic conditions, and hypothermia. 
This method of active transport causes the major bulk of aqueous production. 
 
The rate of formation of aqueous humor is 2.0 to 3.5 microliter per minute. Aqueous 
then enters the posterior chamber. The volume of aqueous in this region is 0.06 ml. 
Aqueous then enters the anterior chamber passing through the pupil. The volume of 
aqueous in the anterior chamber is 0.25 ml. 
 
Aqueous outflow from the anterior chamber is by three routes: the trabecular, 
uveoscleral and uveovortical pathways 
 
1. Trabecular outflow: about 85 to 95% of the aqueous humor leaves the eye by 
the trabecular pathway. Hence, the trabecular outflow is the major route of 
aqueous outflow. Aqueous resistance is encountered at the juxta-canalicular 
region and the inner wall of the Schlemm’s. Further transport of aqueous across 
these structures is done by a process vesicles or vacuole formation. Studies have 
shown that this is a passive transport dependent on pressure. 
 
15 
 
2. Uveoscleral outflow: Aqueous also flows out through the ciliary body and root 
of iris to ciliary muscle to enter the suprachoroidal space. Further drainage is 
through the veins in the ciliary body or choroid. This is a relatively minor 
outflow route which is enhanced by cycloplegic drugs, adrenergic agonists and 
by inducing cyclodialysis. This outflow is lesser on using miotics. In contrast to 
the trabecular outflow, this route is relatively independent of pressure changes. 
 
3. Uveovortical outflow pathway: Studies have shown discernable quantities that 
traverse iris vessels, ciliary muscle and anterior segment of the choroid. This 
pathway finally exits through the vortex veins. 
 
AQUEOUS HUMOR COMPOSITION:  
The aqueous is always compared with the plasma. So in comparison, the aqueous is: 
1. Hypertonic and acidic  
2. Increased ascorbate levels which are 10 to 15 times that in plasma 
3. Paucity of proteins .0.02% proteins compared to the 6.5 to 7% of plasma. 
4. Increased concentration of chloride and lactate. 
5. Decreased levels of sodium and bicarbonate. 
6. Decreased concentration of glucose  carbon dioxide. 
7. Protein levels are equal to that in serum when a turbid aqueous is encountered in 
cases of uveitis. 
8. Albumin: globulin ratio in aqueous is vey much like that in plasma. 
Immunoglobulins in aqueous are a little lesser. 
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AQUEOUS HUMOR FUNCTIONS: 
 
1. Maintenance of the IOP. 
2. A source of glucose and oxygen along with other electrolytes needed for the 
metabolic activities of cornea and lens 
3. Serves to eliminate the products of metabolism 
 
FORMATION AND EGRESS OF AQUEOUS: 
 
- Aqueous formation falls during sleep (drop of around of 40%). It also decreases 
with increased age(about 2% for every 10 years), inflammation, retinal and 
choroidal detachment. Recent studies have shown that aqueous formation is 
relatively pressure insensitive and does not decrease with increase in IOP as was 
believed earlier. 
 
- Parasympathomimetic drugs lead to a contraction of the ciliary muscles. This 
increases the trabecular and decreases the uveo-scleral outflow. Cycloplegics 
which lead to a relaxation of ciliary muscles causes a drop in the trabecular 
outflow while increasing the uveoscleral outflow of aqueous. 
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DEFINITION OF INTRA-OCULAR PRESSURE (IOP) 
 
The consensus definition of normal IOP is that it is the pressure within the eye which 
does not result in glaucomatous damage2, 8. The mean IOP in a normal population is 
15.6 mm of Hg when using Schiotz tonometer and 16 mm of Hg when using the 
Goldmann applanation tonometer. The distribution of IOP is not strictly in accordance 
with Gaussian principles. It is skewed towards higher values. When measuring the 
standard deviation, a value of 2.5 mm of Hg is obtained. Two standard deviations 
from the mean includes 95% of a Gaussian distribution below 21 mm Hg. Hence, the 
upper limit of normal is not entirely correct from a statistical point of view as the 
Gaussian curve is skewed. However, for practical purposes, 21 mm Hg is considered a 
safe limit. 
 
Factors influencing the intraocular pressure: 
- Genetically multifactorial inheritance has been described. 
- There is an increased IOP within older age group. 
- In the age group of 20 - 40 years the IOP is comparable in males and females. 
At advancing age, the mean IOP is slightly more in females 
- Myopia and increased axial length of the globe are associated with higher IOP. 
- Race - IOP is slightly higher in blacks when compared with whites 
- The diurnal variation of IOP has been attributed to plasma cortisol level and its 
changes during the 24 hour period. The maximum IOP is seen in the morning 
hours. Variations are seen within a normal population. 
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- Influence of posture: IOP progressively increases when the patient goes from 
sitting to supine position. It increases further if legs are elevated and the head is 
brought down. All these effects are more pronounced in glaucomatous eyes 
- Valsalva manoeuvre elevates the IOP as it causes an increase in the episcleral 
venous pressure (EVP). 
- Blink and lid squeeze can also lead to considerable IOP increase. 
 
METHODS TO MEASURE THE IOP: 
 
TONOMETRY: 
 
The principle used here is to relate a force needed to deform the globe to the pressure 
inside the globe. Many different models are available. 
 
A. INDENTATION TONOMETRY 
 
The most popular one is the Schiotz tonometer. Its footplate rests on the cornea whilst 
a plunger of specified weight causes an indentation on the cornea which is measured 
by a movement of the needle on a calibrated scale. A truncated cone is formed as a 
result of this deformation.  
 
The fallacy with this instrument is that the indentation itself raises the IOP from Po to 
Pt. Hence an estimate of Po is always dependent upon another variable, the ocular 
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rigidity. It can be understood that a low ocular rigidity (denoted by ‘k’) shows a false 
low IOP. Low ocular rigidity occurs in high myopia, therapy with miotics, prior 
surgery in the eye, vasodilator drug usage, compressible gas used intravitreally, 
collagen disorders like osteogenesis imperfecta and endocrine disease like thyroid 
disorders. Similarly, a high ocular rigidity shows a false high IOP measurement. 
Causes for this condition are high hyperopia and therapy with vasoconstrictor agents. 
 
Apart from these, there are other sources of error like expulsion of intraocular blood 
during indentation leading to lower IOP. Steep or thick corneas tend to displace more 
than normal fluid during indentation. This results in a false high IOP reading. In this 
context, the Moses effect is described wherein the cornea moulds into the small space 
seen around the plunger and within the opening in the tonometer footplate. This 
pushes the plunger up further and yields a false high IOP measurement. 
 
B. APPLANATION TONOMETRY 
 
The most widely used instrument is the Goldmann tonometer. It is considered to be 
the gold standard for IOP measurement. It works on a modification of Imbert Fick 
law. This law is applicable only for infinitely thin and dry spheres. It states that: 
 
Pressure = Force/Area  
Force = Pressure x Area 
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In other words, the external force applied on a sphere is the product of pressure inside 
the sphere and the area of the sphere flattened (applanated) due to this external force. 
A basic prerequisite for this law is that the object should be perfectly spherical, dry, 
infinitely thin and very flexible. The eye does not satisfy these prerequisites. Thus a 
modification of this law is made: 
 
Modified Imbert Fick Law: 
Force + Surface tension = Pressure x Area + Force needed to bend the cornea 
 
If the area is 7.35 mm2 the surface tension equals the force needed to bend the cornea 
and thus the external force is equal to the pressure within the eye. An area of 7.35 
mm2 equals a diameter of corneal applanation of 3.06 mm. When such a small 
applanating head is used, a minute aqueous volume (about 0.5 mm3) is displaced. 
Thus Pt is not very different from Po and ocular rigidity (k) does not have a prominent 
role. 
 
There are few sources of error whilst using the applanation tonometer. False high 
IOPcan be obtained with wide mires, thicker cornea, astigmatism (a factor of of 1 mm 
Hg for every 3 dioptre rise of corneal power), squeezing of lids, holding the breath, 
collars that are tight or Valsalva manoeuvre. In a similar way, false low IOP readings 
may be seen when applanation is performed without fluroscein, in cass of edema of 
cornea, and inadvertant prolongation of corneal contact. The method employed in 
case of marked astigmatism is to take an average of the vertical and horizontal 
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readings. Another method will be to align the red line on the head to the lesser curved 
meridian. 
 
The Goldmann tonometer is one which uses variable force. There are other 
tonometers which use variable force: 
 
- Perkins tonometer is a hand-held instrument. It resembles the Goldmann 
tonometer in its usage methodology. 
- Draeger tonometer uses an electric motor to provide a force needed for 
applanation. 
 
- Mackay-Marg tonomter measures the force needed to maintain the flat foot 
plate of its plunger flush with its sleeve against the pressure used for 
deformation of the cornea. The instrument gives higher values than the 
Goldmann tonometer. Nevertheless, this is an accurate instrument in eyes 
having irregular or scarred corneas. Mackay Marg principle is used in many 
new tonometers like the Tono-Pen. 
 
- Tono Pen is an instrument where the probe causes an indent on the cornea. 
The IOP and reliability of readings are found by a microprocessor at the tip.  
 
- Pneumo tonometer: A pressure sensor monitors the air pressure corneal 
deformation is transferred to surrounding structures. This is then related to the 
22 
 
IOP. Measurements thus obtained are a more thn those seen with the 
Goldmann tonometer. 
 
C. NON-CONTACT TONOMETRY: 
 
The instrument uses a puff of air to deform the cornea. This uses a constant force. The 
time taken from a reference plane to the flattening of the central cornea is related to 
the force needed. It is then calibrated to give a digital display as the IOP. 
 
The interval between subsequent measurements is 1 to 3 msec. The measurements are 
done in an instant and so fluctuation of readings can be seen. It is thus necessary to 
take 3 radings for each eye and calculate the mean. The readings correspond to IOP 
by Goldmann tonometer in the normal range of IOP. The reliability reduces with 
higher levels of IOP. 
 
D. CONSTANT FORCE APPLANATION TONOMETERS 
 
The Maklakov tonometer determines the IOP measuring an area of corneal flattening 
using a predetermined weight. 
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GLAUCOMATOUS DAMAGE OF THE OPTIC NERVE HEAD 
 
THEORIES RELATED GLAUCOMATOUS OPTIC NERVE HEAD 
CHANGES: 
 
Manifestations of ONH changes in glaucoma are purely mechanical alterations due to 
increased IOP9. An increase in the IOP causes to inhibition of both the retrograde and 
orthograde transport within the axons at the lamina cribrosa level. It also leads to 
compression of the axons with resulting compromise. 
 
1. Vascular collapse causes ischemic changes due to intraocular pressure 
increase or coexistant vascular pathology causes obstruction of flow of 
axoplasm contents and subsequent axonal loss. 
2. Vascular & mechanical factors may exist in the same individual. 
 
MICROSCOPIC CHANGES ASSOCIATED WITH GLAUCOMATOUS 
OPTIC ATROPHY: 
 
Neuroretinal rim  loss of the ONH which is seen as enlargement of the cup is due to 
axonal loss and alterations of capillary network and glial support. Loss of tissue 
begins at the lamina cribrosa level. It is brought about by compact comprssion and 
fusion of the plates of lamina cribrosa. A loss of 25 to 35% of total axons is needed 
before visual field loss is detected. 
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Loss of axons could be generalized. But characteristic findings are localised loss at 
the superior and inferior poles of the NRR. This is because the axonal density reaches 
a maximal limit in these areas. Another reason of selective damage here is that large 
sized retinal nerve fibers which are located greater concentration over the superior and 
inferior poles are mechanically more susceptible to damage by elevated IOP.  
 
As compared to adults, cupping in glaucoma occurring in infants or children is 
relatively reversible. This is brought about by an expansile ring of sclera tissue in 
younger ages. Glaucoma when progressing causes a collapse in the plates of the 
lamina cribrosa. This then leads to a bowing of the lamina posteriorly. 
 
Another distinct kind of optic atrophy which creates empty cystic spaces is given the 
name of Schnabel's cavernous atrophy. These spaces stain with special stains for acid 
mucopolysaccharide substances like hyaluronic acid. This discrete phenomenon is 
reported to occur with IOP elevations that are severe and also in atheromatous 
changes of vessels associated with a normal IOP.  
 
MACROSCOPIC CHANGES ASSOCIATED WITH GLAUCOMATOUS 
OPTIC ATROPHY: 
 
Changes in the visual field often follow changes in the optic nerve head. Stereoscopic 
evaluation of the optic nerve head is essential to unmask the subtle contour changes. 
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Documentation of these changes by stereophotography will help in progression 
monitoring. 
 
I. Focal signs of glaucomatous damage are an enlarged cup focally due to 
localised atrophy or notching of NRR. Nerve fiber defects may be 
localized or diffuse and are often seen with the ophthalmoscope. Localised 
pallor of cup with cup changes can occur as cupping due to glaucoma can 
predate pallor. Drance hemmorhages on the nerve fiber layer occur 
frequently in normal tension glaucoma. Saucerisation of disc causing a 
vertical cup elongation and progression of localized neuroretinal rim loss 
are probable signs. 
 
II. Generalized signs like an enlarged c:d ratio with asymmetry of cupping 
and progressively enlarging cup concentrically. 
 
III. A few less specific changes are the laminar dot sign with increased cup 
depth or a displacement of the vessels on the cup nasally and circumlinear 
vessels baring wherein these vessels do not turn near the cup outline but 
instead are bared from the disc margin. A peripapillary atrophy can also 
set in. 
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 FACTORS DETERMINING THE DAMAGE DUE TO GLAUCOMA: 
 
• Intraocular pressure levels 
• Older age groups 
• Associated cardiac complications & coexistent vascular pathology  
• Hereditary factors 
• Scleral aperture size 
• Systemic comorbidities like Diabetes mellitus 
• Myopia 
 
 REVERSIBILITY OF GLAUCOMATOUS CUPPING 
 
• Infants and children may show reversibility in cupping caused by glaucoma 
when  surgical control of IOP has been achieved in the first year itself. 
• Some reports suggest glaucomatous cupping reversal in adults. These are not 
very significant and could occur in early stages of atrophy when significant 
IOP reduction has been achieved by surgery. 
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THE ROLE OF PERIMETRY IN VISUAL FIELD LOSS ASSESMENT IN 
GLAUCOMA: 
 
The visual field is described as the part of the external three dimensional space which 
is simultaneously perceived by the eye that is fixating on a particular target. The 
normal visial field is 60° in superiorly, 75° inferiorly, 110° over the temporal field 
and and 60° in the nasal field. The visual fields were described as an island hill of 
vision in an ocean of darkness by Traquair. The area of maximal sensitivity when the 
retina is in light adapted state is represented by a central peak which corresponds to 
the fovea of the eye10. 
 
Deviations from the shape of the normal line which marks the visual hill that are 
statistically and clinically significant may be taken as a field of vision defect. Patterns 
in apatient who has glaucoma may be some diffuse depressions or localized defects. 
The local defects in glaucoma follow a pattern of the nerve fibers loss which is 
restricted to certain areas. In contrast, diffuse depression shows a generalized loss of 
sensitivity throughout the retina and occurs subsequent to loss of retinal axons in a 
more diffuse and generalized fashion. When compared to local defects, diffuse loss of 
field is relatively less specific for glaucoma damage since it can occur in other ocular 
affections. 
 
A cataract is most often a reason for diffuse depression of the field. A miotic pupil 
refractive errors, fatigability of the patient or a first automated field examination are 
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also likely causes of generalised field depression. Hence, depression of fields in a 
diffuse manner cannot be specifically attributed to glaucoma. 
 
RNFL damage in particular areas of the retina and the ONH when a glaucomatous 
process is ongoing will result in certain characteristic local field defects. These local 
defects tend to correspond with the anatomic distribution of the nerves in the retina. 
Paracentral well defined defects occur early in any damage to the RNFL by glaucoma. 
Such a defect could be absolute at presentation. More often, areas of depressed 
sensitivity surrounded by more sensitive areas are encountered11. 
 
If the loss of axons proceeds unchecked, arcuate fibers of the retina are then involved. 
This manifests as scotoma called the arcuate scotoma. It begins near the blind spot on 
the temporal visual field and arches around fixation to end at the horizontal meridian 
on the nasal side of the field. Following the anatomic distiribution of the nerve 
bundles, the defect is narrow temporally and fans out nasally to occupy a relatively 
larger space. 
 
As mentioned earlier, all arcuate scotomas will terminate at the horizontal plane on 
the nasal side of the visual field. RNFL loss in the inferior and superior fields is not 
often symmetrical. If there is any disparity in their horizontal extent at their junction 
along the raphe, it manifests as a defect called the nasal step. Arcuate scotomas and 
paracentral scotomas are often associated with the nasal step. In about 20%, apart 
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from other scotomas, nasal steps occur alone. Peripheral nasal step defects are the first 
presentation in round 8% of patients. 
 
A few other characteristic field defects occur if the nasal retinal fibers are involved. 
Though the superior and inferior poles are most commonly involved in glaucoma, 
nasal part of the ONH can sometimes be involved. This then leads to damage to the 
radial nerve fibers in the nasal retina. Loss of these fibers manifest on the visual fields 
as wedge defects temporally. Unlike the nasal arcuate defects, these temporal wedge 
defects do not respect the horizontal meridian. In around 2% - 3%, they are the only 
field loss demonstrated.  
 
EARLY FIELD CHANGES – Studies have shown that the most common defects 
are nasal steps and paracentral scotomas. They occur in around 54% and 41% 
respectively. It is also likely that these defects coexist. Arcuate defects and blind spot 
enlargement sre the other common defects which are seen in 20 and 30% respectively. 
Temporal defects are less common and occur in 2 to 3%. It is important to note that an 
early field loss could be either relative or absolute. 
 
BLIND SPOT CHANGES - Siedel scotoma is an enlargement with an elongation of 
the blind spot vertically. Early arcuate defects that are contiguous with the blind spot 
and extend either above or below the horizontal meridian are seen. Blind spot 
enlargement is attributed to the phenomenon of peripapillary atrophy that sets in with 
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advancing glaucomas. Physiologic or pathologic baring of the blind spot may also be 
encountered.  
 
GLAUCOMA PROGRAMS ON THE AUTOMATED PERIMETER- The G1 
program or 32 is very similary to the 30 – 2 program on the Humphrey’s perimeter. 
They test the central 30° of the field with a 6° separation between each tested point 
along the horizontal or vertical meridians. 24-2 program on the Humphrey eliminates 
testing of the edge points from the 30-2 program apart from the areas of nasal step. It 
checks only the central 24°. It is better than the 30-2 as the edge point data are nor 
very reliable and are influenced by external factors. 
 
RETINAL NERVE FIBER LAYER THINNING AND THE ROLE OF OCT: 
 
The principle behind the working of the Optical coherence Tomography (OCT) is low 
coherence interferometry. 
 
Interferometry is done using a white beam (ie., low coherence light). By the use of 
such light rays, images and measurements can be done at high resolution. The 
resolution of latest machines available in the market range from 10 to 20 microns. The 
instrument basically compares the properties of light reflected from the retina with a 
reference beam. The interferometer is using in the process of comparing the two light 
beams12. 
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o RNFL thickness can be measured with OCT. It is very useful in glaucoma 
diagnosis and detection of progression of the disease.  
o Identifiable retinal nerve fiber layer thinning occurs before field defects and 
obvious cupping set in.  
o RNFL thinning correlates with visual field defect and NRR loss in the more 
advanced stages of the disease whereas RNFL thinning seems out of 
proportion to field loss in early stages of glaucoma. Early glaucoma detection 
is possible with monitoring of the RNFL thickness and NRR. 
o Glaucoma cannot be identified based on the local thickness of RNFL. Many 
age related and individual factors play a role in their location and extent.  
o As a general rule, the RNFL is thick inferiorly and superiorly in normal eyes. 
In a glaucomatous eye, it is more likely to be thinned out and flatter. 
o The nasal retina is the least likely site of glaucomatous damage. 
o Similarly other ocular anatomic variations (eg., Myopia) tend to affect the 
temporal retina. So the nasal retina is relatively spared. 
o The distance from margin of the disc is inversely related to the thickness of the 
RNFL. 
 
INDICATIONS FOR SURGERY 
 
The surgical decision needs to consider the risk : benefit for the patient. A lower IOP 
is beneficial to the eye but the loss of vision is a risk. So saving vision with surgery 
must be paramount13, 14. 
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Surgery for glaucoma is indicated if: 
- Medical therapy fails to lower the IOP. 
- Laser surgery is not beneficial 
- The compliance with medical therapy is likely to be poor.  
 
1. Physicians should check IOP more than once and various times of the day 
when calculating the baseline IOP before surgery. If IOP is markedly 
increased, a single determination may be enough. 
2. Glaucoma Progression taking both the structural and functional integrity of the 
optic nerve should be kept in mind. 
3. Further care of the glaucoma patient needs careful periodic evaluation of 
structure and function of the optic nerve. 
4. Estimating the rate or risk of progression is needed. Age should be considered 
when planning treatment. An older patient with minimal progression may 
suffer no effect on quality of life during his life.  
5. Risk factors associated with glaucoma progression are found from prospective 
studies15. The AGIS has showed that older age, males, lower education, 
diabetic status are a risk. Similarly, CNTGS showed that females and migraine 
are risk factors. The EMGT uncovered higher IOP, pseudo-exfoliation, visual 
fields progression during follow up, haemorrhages over the disc as risk 
factors. These risk factors will change the target IOP or lower the threshold for 
surgery16, 17.  
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6. Loss of vision in the other eye from glaucoma lowers the threshold IOP for 
surgical consideration. Family history of glaucoma will require a close 
observation of the patient.  
7. Surgery as a primary treatment is indicated based on some socioeconomic or 
logistic reasons. All patients need not undergo primary surgery. 
8. Compared to those with early disease, those patients with central field loss 
need early surgery. 
 
GLAUCOMA SURGERIES: 
 
Glaucoma drainage procedures which are also known as external filtration surgery is 
performed in case there is no flow block internally and the IOP remains high inspite 
of using maximal medical therapy. Two types of these filtration procedures are 
described. They are the guarded and full-thickness procedures. Other changes to the 
basic steps are being followed of late. 
 
GUARDED FILTRATION PROCEDURE (TRABECULECTOMY): 
 
This is the procedure of choice in hitherto unoperated eyes. Suture modification for 
further IOP adjustment is now being employed. 
 
Trabeculectomy offers better and long term IOP lowering than NPGDS. Use of anti 
fibrotic agents should be based on individual case profile. This is relevant to initial 
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and repeat surgery. Presurgical inflammation of the conjunctiva and postsurgical 
inflammation of the conjunctiva and ocular contents should be controlled with 
steroids. Success of trabeculectomy depends on postsurgical care.  Early recognition 
of complications and prompt intervention increases the success of the procedure. Late 
bleb related infection is a serious threat and patients need to be warned about them. 
Immediate attention in these cases is important for visual prognosis. 
    
TRABECULECTOMY TOGETHER WITH CATARACT EXTRACTION: 
 
A combination of these surgeries is needed when surgery for intraocular pressure 
(IOP) lowering is appropriate and a vision affecting cataract is also present. Glaucoma 
patients who are undergoing cataract surgery do not always need combined surgery. 
In order to avoid problems of high postoperative IOP these procedures need to be 
considered for patients taking many medications and in those with relatively advanced 
glaucoma. The desired IOP level of after surgery, the severity of disease and the likely 
benefit in vision quality after cataract extraction will dictate the decision to perform a 
combined procedure.  
 
Differentiation between a one site or a two site approach for both surgeries depends 
on the surgeons comfort. There is little evidence to choose from a limbal or a fornix 
based approach for surgery. In patients with cataract and stable glaucoma, if 
subsequent trabeculectomy is needed, a clear corneal approach can be use at the first 
sitting. 
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FULL-THICKNESS SURGERIES:  
 
There are many procedures. Few of them are thermal sclerostomy (Scheie procedure) 
which was popular some time ago, sclerectomy, trephination and iridencleisis. These 
are only of historical interest now 
 
GLAUCOMA DRAINAGE DEVICES (GDD): 
 
Glaucoma drainage devices are used if it is anticipated that trabeculectomy is might 
not be successful owing to logistical or socioeconomic issues. Prevention of early 
postoperative hypotony largely depends on restriction of flow of aqueous humor from 
the eye. GDDs that lack check mechanism will need a ligature. An internal stent or 
some form of flow controlling mechanism can also be employed. Surface area of the 
plate of the GDD is directly related to the decrease in IOP18. 
 
Scarring around the plate is often the most important cause of failure of GDDs. 
Success with GDDs is not enhanced with antifibrotic agents. In a patient who has had 
a pars plana vitrectomy, pars plana positioning of the GDD can be done. It is also 
attempted in someone for whom the seton cannot be safely inserted into the AC. 
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NON PENETRATING GLAUCOMA DRAINAGE SURGERY (NPGDS): 
 
This recent advancement gives an alternative surgical for lowering of IOP in 
glaucoma when compared to the conventional approach of trabeculectomy. Nd:YAG 
laser goniolysis can be a part of the surgery when employed postoperatively. External 
filtration with deep sclerectomy will increase the success rate of the procedure. 
Viscocanalostomy has not shown high IO P drop after surgery. 
 
Deep sclerectomy provides a better IOP control than viscocanalostomy. There are 
ongoing studies in this regard.Success of subsequent trabeculectomy is affected by 
prio NPGDS. 
 
CYCLODESTRUCTIVE PROCEDURES: 
 
The procedure used in refractory glaucoma where trabeculectomy or GDDs could fail 
or induce surgical complication is one of the cyclodestructive procedures. Of the 
many such procedures available, cyclophotocoagulation using the laser diode (the G-
probe laser) is most preferred.   
 
G probe cyclophotocoagulation by the transscleral method is done when maximal 
medical treatment, trabeculectomy or drainage implant surgery cannot be done due to 
any reason. Transillumination of the eye to identify the ciliary location body may be 
useful before transscleral cyclophotocoagulation. This is specifically done in 
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morphologically abnormal eyes.  Steroids and cycloplegic drugs are used to reduce 
the complications and irritation that may be present. Treatment effectiveness needs to 
be assessed after 1 month. By then, the option of repeating the procedure can be 
feasible. Minimal laser application which can be repeated is better than high dose 
treatment in a single sitting. This will help to reduce the complications of treatment. 
 
TRABECULECTOMY WITH ANTI-METABOLITES: 
 
MITOMYCIN C (MMC): 
 
Streptomyces caespitosus is the organism from which this anti-neoplastic antibiotic is 
developed. A complete inhibiton of proliferation of fibroblast is seen on tissue culture 
when this agent has been used. Trabeculectomy can thus be made more effective with 
its use. It is seen to increase the success surgeries done for glaucoma. Previously, 
MMC was used in the dose of 0.5 mg in one ml. It was used on the sub-conjunctival 
tissues and left in place for 6 minutes.  
 
However, recent studies show that MMC used for 2 minutes in the dose of 0.02% is as 
effective as using 0.5mg in one ml. Hypotonous maculopathy is the most feared 
complication associated with use of MMC. 
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5-FLUOROURACIL: 
 
Blockade of DNA synthesis by this pyrimidine analogue which falls under the class of 
anti-metabolite is the mechanism employed to decrease proliferation of fibroblasts in 
cell culture. Increase in the bleb formation after surgery is seen by using sub-
conjunctival injections of 5-FU. The most serious side effect is corneal toxicity19. 
Sustained release conjunctival implants are undergoing clinical trials. The use is in the 
dose 30 to 50 mg per ml during surgery. It is placed with a cellulose tipover the site 
for 5 minutes. Now, 5FU has been replaced by most experts with MMC. 
 
Use of 5FU as an adjunct is not practiced now as evidence points that that it is not as 
effective. Trabeculectomy alone is more successful than combined procedures for IOP 
decrease. Results of previous trabeculectomy surgery are often sdversely affected by 
subsequent cataract surgery20. 
 
TRABECULECTOMY WITH COLLAGEN IMPLANTS: 
 
The biodegradable collagen implant is being used as a newer modality for increasing 
the long term success of trabeculectomy. Cellular regeneration around poorly healed 
wounds with the use of bioengineered tissues is now used in many surgeries21, 22. 
Production of these implants is by the use of primary cells implanted into scaffolding 
made of synthetic polymer. The matrix is then cultured. The regenerative process 
employs either species specific cells which may be taken from tissues adjacent the 
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wound23, 24. Other cells developed invitro like the stem cells are also used. Formation 
of structures that are very similar to parent tissue can be seen after natural 
biodegradation of scaffold. Prevention of scarring after trabeculectomy by the implant 
is by a process of subconjunctival wound healing modulation and architectural 
streamlining. There is also a reorganization of the newly forming fibroblasts and 
adjacent extracellular substances. 
 
The success of trabeculectomy is increased by use of a three dimensional collagen 
based glycosaminoglycan structure that is inherently porous. A space in between the 
conjunctiva and sclera is use to place the implant. This then acts like a spacer. It 
mainly helps in  maintaining the patency of the subconjunctival area. Modulation of 
wound healing is the main mechanism. This is very different from the action of 5FU 
or MMC. Collagen implants  do not affect proliferation of fibroblasts in a direct way. 
They direct the regenerating collagen to be deposited in a orderly pattern rather than 
randomly25, 26. 
 
The risk of postsurgical infection is not very prominent as the surface immunity of the 
conjunctival tissue is not altered. Infection rates are less than those with 5FU and 
MMC. 
 
Current studies show that the biodegradable collagen implant is very safe and 
efficacious. Over-filtration, a problem associated with MMC and 5FU is not seen with 
these collagen implants. Thus in patients with a history of hypotonous maculopathy in 
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the fellow eye after MMC based trabeculectomy, it is an option. Patients who have 
blepharitis in whom antifibroblastic agents can cause eye infection are also suitable 
candidates27, 28. Combined surgery for cataract extraction and trabeculectomy with 
these collagen implants is very feasible for glaucoma patients on two drugs and 
significant lens changes. 
 
To conclude, scar formation along the pathway of filtration leads to trabeculectomy 
failure over the course of time29. This occurs more often with patients who have 
undergone previous surgery for glaucoma. Mitomycin C and 5-fluorouracil are 
antifibrotic agents that are associated with some significant complications like cystic 
blebs, bleb leak, hypotonous maculopathy and endophthalmitis. As of today, studies 
show that the biodegradable collagen implant is a simple and effective option for the 
treatment of refractory glaucoma. It is seen to be safer than antifibrotic agents in the 
prevention of scar formation after trabeculectomy30, 31. 
 
In our study, we have used the collagen matrix available in the form of a 6 x 2 mm 
disc as shown in the picture. 
 
COMPLICATIONS OF TRABECULECTOMY 
 
- Buttonholing the conjunctiva 
- Flat anterior chamber with hypotony 
- Flat anterior chamber in normotensive and hypertensive eyes 
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- Malignant glaucoma 
- Suprachoroidal hemorrhage 
- Intraoperative flat anterior chamber 
- Hyphema 
- Intraocular infection 
- Sympathetic ophthalmia 
- Filtration failure 
- Dellen 
- Hypotonous maculopathy 
 
BLEB RELATED COMPLICATIONS 
 
- Thin-walled blebs 
- Bleb migration onto cornea 
- Diffuse blebs 
- Overfunctioning blebs 
 
DEFINITION OF SURGICAL SUCCESS: 
 
The outcome of glaucoma surgery can be graded based on various parameters at the 
end of followup. In this regard, complete success and qualified success are described. 
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COMPLETE SUCCESS: When the intraocular pressure is maintained less than 21 
mm of Hg throughout the study period without the use of additive therapy and when 
there is no progression of field defects by automated perimetry nor loss of RNFL by 
OCT, complete success is said to be attained. 
 
QUALIFIED SUCCESS: If the intraocular pressure is maintained at less than 21 mm 
of Hg with the use of additional therapy, the surgery qualifies as success on limited 
terms. 
UNSUCCESSFUL: When the IOP is not consistently less than 21 mm of Hg and 
progression of field defects and RNFL is not halted despite use of additional therapy, 
then the filtering surgery is termed unsuccessful. 
 
MOOREFIELDS BLEB GRADING: 
 
A photograph based grading system for the bleb morphology has been introduced by 
the Moorefields Eye Hospital. A photograph of the patient’s eye is taken with the 
patient looking down exposing a maximum part of the superior conjunctiva and the 
bleb. This photograph is then compared to a standard set of photographs prepared by 
the Moorefields Eye Hospital and the patients bleb is graded based on three criteria: 
the bleb area, bleb height and bleb vascularity.  
1. Area of the bleb 
 - Central area: Grade 1 to 5 
 -Maximal area: Grade 1 to 5 
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2. Height of the bleb 
 - Highest point on the bleb: Grade 1 to 4 
 
3. Bleb vascularity 
 - Central area: Grade 1 to 5 
 - Maximal area: Grade 1 to 5 
 - Conjunctiva away from the bleb: Grade 1 to 5 
 
This system helps in evaluating the functional status of the surgical blebs. It is also a 
document for future reference and progression monitoring 
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Figure 1. Structures in the angle of the anterior chamber and the pathway of aqueous outflow. 
 
 
 
 
Figure 2. An ideal bled seen after trabeculectomy that is avascular, diffuse and microcystic in appearance. 
 
 
 
 
Figure 3. UBM showing a well formed functional bleb. 
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Figure 4. The collagen implant of 6 mm diameter and 2 mm height used in the study. 
 
 
 
Figure 5. Implant seen between the conjunctiva and the sclera 
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Figure 6. A histologic section from an experimental eye shows that the implant is covered by conjunctival 
epithelium 1 month post-operatively 
 
 
 
Figure 7. By the 6th postoperative month, the implant’s polymer matrix has degraded, leaving behind a 
connective tissue framework that forms the bleb. 
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OBJECTIVES OF THE STUDY 
An analytical study of the surgical outcomes of trabeculectomy with and without 
ologen implant was done. The aims of the study were 
• To evaluate the success rate of trabeculectomy with OloGen implant and to 
compare the outcomes with plain trabeculectomy. 
• To look for any local effects due to the implant & bleb related complications 
 
METHODOLOGY (MATERIALS & METHODS) 
 
Subject Selection: 
 
Patients presenting to the Glaucoma services of RIO-GOH over a period of 2 
years (July 2010 to June 2012).  
 
Screening & Procedure:  
 
  39 Glaucomatous eyes of 35 patients meeting the eligibility criteria were 
enrolled in this prospective study. After obtaining the informed consent from the 
patient detailed history taking followed by thorough glaucoma evaluation- Visual 
acuity recording by the Snellen’s chart, IOP by both non-contact tonometry and by 
Goldmann applanation tonometry (after correction for the central corneal thickness by 
pachymetry), slit lamp examination & gonioscopy by Goldmann single mirror, fundus 
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examination by 78D lens, fields by Octopus automated perimetry (AP) & ONH 
topography with retinal nerve fiber thickness (RNFL thickness) by Optical Coherence 
Tomography (OCT) was done.  
 
The patients are randomly allotted into 2 groups. Those in group A underwent 
trabeculectomy alone while those in group B underwent trabeculectomy with an 
Ologen implant. 20 eyes were allotted to group A and 19 eyes were allotted to group 
B. In the trabeculectomy group, there were 9 eyes with POAG, 9 eyes with PACG and 
2 eyes with developmental glaucoma. Similarly the trabeculectomy with OloGen 
group had 8 eyes with POAG, 8 eyes with PACG and 3 eyes with developmental 
glaucoma.  
 
Trabeculectomy was done by fornix based conjunctival peritomy. Thereafter, 
a 3x3 mm triangular limbus based scleral incision was fashioned in both groups. A 
triangular partial thickness scleral flap is raised and 2x2 mm of the deep sclera was 
removed using Kelly’s punch. A peripheral iridectomy (PI) was performed. The 
scleral flap was replaced and secured in place by two interrupted 10-0 polyamide 
sutures and the conjunctiva sutured over the wound with 8-0 vicryl sutures. In those 
patients in group B alone, the Ologen implant was placed over the scleral flap before 
suturing the conjunctiva. The implant measuring 6 mm in diameter and 2 mm in 
thickness was removed from its sterile packing and after ensuring minimal exposure  
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to the ambient air, was placed above the triangular flap. Suturing of the scleral 
flap was done with minimal resultant tension on the sutures. However, the conjunctiva 
was secured to be water tight. 
 
Inclusion Criteria:                                   
 
o Eyes with advanced glaucomatous damage due to open or angle closure 
glaucoma. 
o Patients showing progression of field defects by perimetry inspite of topical 
medications. 
 
Exclusion Criteria:                                 
 
o All cases of secondary open or angle closure glaucoma 
o Diagnosed cases of macular dystrophy or degeneration. 
o Patients with retinal vascular occlusion (Retinal artery or vein) 
o Patients with diabetic or hypertensive retinopathy. 
o Patients with early stages of primary open angle glaucoma who could be 
managed with topical medications. 
o Patients with early stages of primary angle closure glaucoma for whom laser 
iridotomy would be appropriate 
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Follow up Procedures / Visits:  
 
o Patients were examined at discharge, 1st week, 1st month, 3rd month, 6th month, 
1st year and 2nd year. 
o Visual acuity, IOP by both non-contact tonometry and by Goldmann 
applanation, fundus examination by 78D lens are done at every visit. 
o Angle study with Ziess 4 mirror & visual fields by Octopus perimetry are done 
every 6 months. 
o ONH topography with RNFL thickness by OCT is to be repeated after a year. 
o Ultrasound Biomicroscopy (UBM) was done in selected patients. 
 
Assessments of Parameters: 
 
Periodic examination of visual acuity, IOP, evaluation of disc by 78 D, anterior 
chamber angles by gonioscopy, visual fields by AP, assessment of RNFL for 
documentation of progression.   
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SEX DISTRIBUTION 
Table 2. Distribution between males and females 
S. 
NO 
SEX 
TRABECULECTOMY GROUP 
(NO. OF EYES) 
TRABECULECTOMY WITH 
OLOGEN IMPLANT GROUP 
(NO. OF EYES) 
1. MALE 10 11 
2. FEMALE 10 8 
 
Figure 9. Distribution of eyes between the sexes in the trabeculectomy group 
’ 
 
Figure 10. Distribution of eyes between the sexes in the trabeculectomy with OloGen group 
 
As is seen from the above table and figures, males and females were equally 
distributed in both groups under study. Statistical analysis for difference between the 
1010
MALES
FEMALES
11
10 MALES
FEMALES
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groups done using the Chi square test showed a p value of 0.621 which is not 
significant. 
 
DISEASE PATTERNS IN THE TWO GROUPS 
Table 3. Diagnosis of the eyes enrolled for the study 
S. NO SEX 
TRABECULECTOMY 
GROUP 
(NO. OF EYES) 
TRABECULECTOMY WITH 
OLOGEN IMPLANT GROUP 
(NO. OF EYES) 
1. POAG 9 8 
2. PACG 9 8 
3.  
Developmental 
Glaucoma 
2 3 
TOTAL 20 19 
In the trabeculectomy group, there were 9 eyes with POAG, 9 eyes with PACG and 2 
eyes with developmental glaucoma. Similarly the trabeculectomy with OloGen group 
had 8 eyes with POAG, 8 eyes with PACG and 3 eyes with developmental glaucoma.  
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OPTIC DISC:CUP RATIO AT PRESENTATION 
Table 8. ONH cup: disc ratio 
S. 
NO 
C:D RATIO 
TRABECULECTOMY 
GROUP 
(NO. OF EYES) 
TRABECULECTOMY WITH 
OLOGEN IMPLANT GROUP 
(NO. OF EYES) 
1. <0.4 - - 
2. 0.4 1 1 
3. 0.5 2 2 
4. 0.6 1 1 
5. 0.7 3 3 
6. 0.8 7 6 
7. 0.9 6 6 
As seen from table 8, 30% of patients in the trabeculectomy group and 32% of 
patients in the OloGen group had an advanced cupping of 0.9 at the time of surgery.  
 
EFFECT OF TRABECULECTOMY ON OCULAR PARAMETERS OVER A 2 
YEAR FOLLOW-UP 
Table 9. Ocular parameters after trabeculectomy surgery over a two year period 
S.N
O 
PARA. 
STUDIED 
PRE 
SURG. 
POST SURGERY 
P VALUE 1ST 
WEEK 
1ST 
MONTH 
3RD 
MONTH 
6TH 
MONTH 
1ST 
YEAR 
2ND 
YEAR 
1. IOP BY 
GAT 
29.65 
+ 8.16 
18.20 + 
6.35 
17.16 + 
3.53 
18.20 + 
4.12 
18.85 + 
3.65 
19.70 
+ 3.95 
21.05 
+ 4.48 
<0.01** 
2. 
CUP: 
DISC 
0.77 + 
0.14 
0.76 + 
0.15 
0.76 + 
0.15 
0.76 + 
0.15 
0.76 + 
0.15 
0.76 + 
0.15 
0.77 + 
0.13 0.016* 
3. AP LV 
24.05 
+ 
19.64 
- - - 
19.31 
 + 
 16.64 
16.60 
+ 
13.50 
18.53 
+ 
11.04 
0.248 
4. 
OCT 
RNFL 
103.37 
+ 
17.79 
- - - 
102.89 
 + 
 18.12 
101.53 
+ 
17.07 
101.96 
+ 
17.30 
0.050* 
** Significant at 1% 
* Significant at 5% 
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Figure 15. IOP levels monitored for a period of two years after trabeculectomy surgery 
 
 
 
Our study showed a significant drop in the IOP over a two year period in eyes that 
underwent trabeculectomy. Data was analysed using the Friedman non-parametric test 
and the p value was less than 0.001. A significant difference was also noted in the c:d 
ratio after two years with the p value being 0.016. There was no significant difference 
in the loss variance. The RNFL thickness, however, showed a significant drop (p 
value of 0.05). The findings were comparable to the study by Papaconstantinou et al24 
which was published in 2010. 
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EFFECT OF TRABECULECTOMY WITH OLOGEN IMPLANT ON OCULAR 
PARAMETERS OVER A 2 YEAR FOLLOW-UP 
 
Table 10. Ocular parameters after trabeculectomy surgery  with OloGen implant  
over a two year period 
 
S.NO PARA STUDIED 
PRE  
SURG. 
POST SURGERY 
P VALUE 1ST 
WEEK 
1ST 
MONTH 
3RD 
MONTH 
6TH 
MONTH 
1ST YEAR 
2ND 
YEAR 
1. 
IOP BY 
GAT 
29.63 + 
7.73 
23.21 
+ 6.51 
19.63 + 
7.41 
19.41 + 
6.57 
17.76 + 
4.35 
16.88 + 
2.99 
16.67 + 
2.73 
<0.001** 
2. 
CUP: 
DISC 
0.75 + 
0.15 
0.75 + 
0.15 
0.75 + 
0.15 
0.75 + 
0.16 
0.77 + 
0.15 
0.77 + 
0.15 
0.78 + 
0.13 
0.062 
3. AP LV 
26.97 + 
20.90 
- - - 
19.08 + 
14.12 
20.00 + 
13.10 
16.18 + 
11.85 
0.225 
4. OCT 
RNFL 
103.35 
 + 
19.96 
- - - 
103.64  
+ 
 19.74 
103.07 
 + 
 18.39 
104.14 
 + 
18.34 
0.549 
 
** Significant at 1% 
* Significant at 5% 
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Figure 16. IOP levels monitored for a period of two years after trabeculectomy 
surgery with OloGen implant 
 
 
A two year follow-up of patients who underwent trabeculectomy with the OloGen 
implant showed a significant drop in the IOP. Statistical analysis performed with the 
Freidman test showed a p value of less than 0.001. Subsequent analysis did not show 
any statistically significant difference in terms of change in the c:d ratio, loss variance 
or RNFL thickness. 
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COMPARISONS OF OUTCOME OF TRABECULECTOMY AND 
TRABECULECTOMY WITH OLOGEN OVER A FOLLOW-UP OF 2 YEARS 
 
a. Measurement of intra-ocular pressure by the Goldman applanation tonometer 
Table 11. Comparitive IOP levels during follow-up in the two groups 
S. 
NO  
IOP BY GAT 
BEFORE 
SURGERY 
AFTER SURGERY 
1ST 
WEEK 
1ST 
MONTH 
3RD 
MONTH 
6TH 
MONTH 
1ST 
YEAR 2
ND YEAR 
1. 
TRABECULECTOMY 
GROUP 
29.65 + 
8.16 
18.20 
+ 6.35 
17.16 + 
3.53 
18.20 
+ 4.12 
18.85 
+ 3.65 
19.70 
+ 3.95 
21.05 + 
4.48 
2. 
TRABECULECTOMY 
WITH OLOGEN 
GROUP 
29.63 + 
7.73 
23.21 
+ 6.51 
19.63 + 
7.41 
19.41 
+ 6.57 
17.76 
+ 4.35 
16.88 
+ 2.99 
16.67 + 
2.73 
3. P VALUE 0.994 0.020* 0.187 0.489 0.415 0.019* 0.001** 
** Significant at 1% 
* Significant at 5% 
 
Figure 17. Comparitive IOP levels during follow-up in the two groups 
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The intra-ocular pressure was measured in all patients during follow-up. They 
were grouped according to the surgery performed and the IOP values between the 
groups at every follow-up were compared and statistically analysed using the 
Independent Sample t test. While there was no significant difference between the two 
groups before surgery, IOP values were significantly more in the OloGen group at the 
1st week of follow-up. However, eyes in the OloGen group had significantly lesser 
IOP levels at the 1st and 2nd year of follow-up. The findings were comparable to the 
study by Papaconstantinou et al24 which was published in 2010. Similar results were 
obtained in India by Tanuj et al31. 
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b. Measurement of the optic cup : disc ratio 
Table 12. Comparision of c:d ratio during follow-up in the two groups 
S. NO  
CUP : DISC RATIO 
BEFORE 
SURGERY 
AFTER SURGERY 
1ST 
WEEK 
1ST 
MONTH 
3RD 
MONTH 
6TH 
MONTH 
1ST 
YEAR 
2ND 
YEAR 
1. 
TRABECULECTOMY 
GROUP 
0.77 + 
0.14 
0.76 
+ 
0.15 
0.76 + 
0.15 
0.76 + 
0.15 
0.76 + 
0.15 
0.76 
+ 
0.15 
0.77 
+ 
0.13 
2. 
TRABECULECTOMY 
WITH OLOGEN 
GROUP 
0.75 + 
0.15 
0.75 
+ 
0.15 
0.75 + 
0.15 
0.75 + 
0.16 
0.77 + 
0.15 
0.77 
+ 
0.15 
0.78 
+ 
0.13 
3. P VALUE 0.744 0.962 0.962 0.953 0.911 0.911 0.868
 
 
Figure 18. Comparision of c:d ratio during follow-up in the two groups 
 
In our study, comparison of the C:D ratio did not show any significant difference 
before surgery nor at any stage of follow-up. 
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c. Measurement of the loss variance seen on the octopus automated perimetry 
Table 13. Comparision of Loss Variance during follow-up in the two groups 
S. 
NO  
LOSS VARIANCE IN OCTOPUS AP 
BEFORE 
SURGERY 
AFTER SURGERY 
6TH 
MONTH 
1ST YEAR 2ND YEAR 
1. 
TRABECULECTOMY 
GROUP 
24.05 + 19.64 
 
19.31 + 
16.64 
 
16.60 + 
13.50 
 
18.53 + 
11.04 
 
2. 
TRABECULECTOMY 
WITH OLOGEN 
GROUP 
26.97 + 20.90 
 
19.08 + 
14.12 
 
20.00 + 
13.10 
 
16.18 + 
11.85 
 
3. P VALUE 0.690 0.968 0.483 0.573 
 
Figure 19. Comparision of Loss Variance during follow-up in the two groups 
 
Analysis of the Loss variance obtained by octopus automated perimetry in all eyes 
showed a gradual decline in LV over a two year period. Nevertheless, no significant 
difference could be demonstrated between the two groups at any stage of follow-up 
by statistical analysis. 
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d. Measurement of the retinal nerve fiber layer (RNFL) thickness by OCT 
Table 14. Comparision of RNFL thickness during follow-up in the two groups 
S. 
NO  
RNFL THICKNESS IN OCT 
BEFORE 
SURGERY 
AFTER SURGERY 
6TH 
MONTH 
1ST YEAR 2ND YEAR 
1. 
TRABECULECTOMY 
GROUP 
103.37 + 
17.79 
 
102.89 + 
18.12 
101.53 + 
17.07 
101.96 + 
17.30 
2. 
TRABECULECTOMY 
WITH OLOGEN 
GROUP 
103.35 + 
19.96 
 
103.64 + 
19.74 
103.07 + 
18.39 
104.14 + 
18.34 
3. P VALUE 0.999 0.911 0.805 0.728 
 
Figure 20. Comparision of RNFL thickness during follow-up in the two groups 
 
The mean RNFL average at the end of a two year period was more in the OloGen 
group. Statistical analysis using the independent sample t test did not show any 
difference between the two groups.  
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EFFECT OF SURGERY ON VISUAL ACUITY AFTER TWO YEARS 
Table 15. Status of the visual acuity over a follow-up of two years 
 
 
TRABECULECTOMY GROUP 
(NUMBER OF EYES) 
TRABECULECTOMY WITH OLOGEN GROUP 
(NUMBER OF EYES) 
IMPROVED 5 7 
DETERIORATED 8 5 
NO CHANGE 7 5 
 
Visual acuity was checked at the end of two years and compared with the pre-
operative vision. Statistical analysis using the Chi square test to compare the 
outcomes in both groups showed a p value of 0.83 which is not significant.  
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MOOREFIELDS BLEB GRADING: 
Table 16. Grading of the blebs using the Standard Moorefields Bleb Grading Photographs 
BLEB CHARACTERISTICS TRABECULECTOMY 
GROUP 
(NUMBER OF EYES) 
TRABECULECTOMY 
WITH OLOGEN GROUP 
(NUMBER OF EYES) 
GRADE GRADE 
I II III IV V I II III IV V 
 
AREA OF THE 
BLEB 
1a   Central area 
0 14 5 1 0 0 15 2 0 0 
1b  Maximal 
area 0 15 5 0 0 0 3 10 4 0 
HEIGHT OF 
THE BLEB 
 
Highest point 10 5 4 1 - 2 11 4 0 - 
 
BLEB 
VASCULARITY 
(GRADE 1 TO 5) 
3a central area 2 16 2 0 0 1 13 2 1 0 
3b maximal area 
 1 18 1 0 0 1 9 5 2 0 
3c conjunctiva  
not forming the 
bleb 
0 16 4 0 0 0 15 2 0 0 
 
Grading of the bleb in each eye was done using the Moorefields bleb grading system 
(MBGS). From the table 16, it is seen that patients with Ologen implants had larger 
and more diffuse blebs. Patients undergoing trabeculectomy alone had blebs which 
were similar in area but flatter compared to the OloGen group. Blebs seen in this 
study were similar to the study group of Tanuj et al31 and were large and diffuse. 
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SUCCESS RATE OF TRABECULECTOMY WITH AND WITHOUT THE OLOGEN IMPLANT: 
Table 17. Outcome parameters for both groups after a one year follow-up 
S. 
NO 
OUTCOME OF 
SURGERY 
TRABECULECTOMY 
GROUP 
(NUMBER OF EYES) 
TRABECULECTOMY 
WITH OLOGEN 
GROUP 
(NUMBER OF EYES) 
1. COMPLETE SUCCESS 12 13 
2. QUALIFIED SUCCESS 4 2 
3. NEITHER 4 2 
 
Table 18. Outcome parameters for both groups after a two year period 
S. 
NO 
OUTCOME OF 
SURGERY 
TRABECULECTOMY 
GROUP 
(NUMBER OF EYES) 
TRABECULECTOMY 
WITH OLOGEN 
GROUP 
(NUMBER OF EYES) 
1. COMPLETE SUCCESS 9 11 
2. QUALIFIED SUCCESS 5 3 
3. NEITHER 6 3 
 
Applying the aforementioned criteria, after one year of follow-up, surgery was a 
complete success in 76% of the patients in the trabeculectomy with the OloGen 
implant group and 60 % in the trabeculectomy group. At the end of two years of 
follow-up, the rate of complete success dropped to 65% in the trabeculectomy with 
the OloGen implant while it was 45% in the trabeculectomy group. The result of 
surgery could neither be termed a complete success nor qualified success in 17% of 
the patients in the OloGen group and 30% of patients in the trabeculectomy group. 
Success rates were obtained with other studies are very similar to our study24,27. One 
study also shows a complete success in almost all with OloGen implants who had 
additional MMC31. 
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INCIDENCE OF COMPLICATIONS WITH OLOGEN IMPLANT  
 
Table 19. Complications encountered with the use of the OloGen implant 
 
S. 
NO 
COMPLICATIONS NUMBER OF EYES PERCENTAGE 
1. ALLERGIC REACTION 4 23.6% 
2. OVERHANGING BLEB 2 11.8% 
3. ENCYSTED BLEB 3 17.6% 
4. AVASCULAR BLEBS 1 5.9% 
5. BLEB LEAK 0 - 
6. BLEBITIS 0 - 
 
Most common side effect encountered in 23.6% of patients having the OloGen 
implant was an allergic reaction to the implant which presented with localized 
congestion and irritation over the bleb area. All these patients were uniformly treated 
with Azelastine eye drops four times a day. 3 patients obtained relief within a week 
and one patient needed usage of the drops for a month. Large overhanging blebs were 
seen in 2 patients while 3 patients had a small encysted bleb. In the study published 
by Tanuj et al31, hypotony and bleb leaks were also noted. However, we did not 
encounter any of these complications. 
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Figure 21. Immediate post-op picture showing the collagen implant in situ. 8-0 
vicryl sutures used for conjunctival closure are also seen. 
 
Figure 22. Allergic reaction to the implant with conjunctival congestion. 
 
 
Figure 23. Well formed bleb after degradation of the collagen implant 8 months 
postoperatively. 
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Figure 24. Larger diffuse bleb seen after implant integration at 1 year after 
surgery 
 
 
Figure 25. Localised encysted bleb. 
 
 
 
Figure 26. Grade 4 conjunctival vascularity by Moorefields Bleb grading. 
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Figure 27. Encysted avascular bleb. 
 
 
 
Figure 28. Flat diffuse bleb after plain trabeculectomy. The triangular scleral 
flap is seen. 
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Figure 29. UBM showing a partially degraded 
implant with a sub-conjunctival aqueous lake. 
 
 
 
 
 
Figure 30. RNFL analysis by OCT showing thinning 
of the superior and inferior RNFL. 
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DISCUSSION 
In order to compare the success rates of trabeculectomy and trabeculectomy 
with a collagen implant, patients who satisfied the eligibility criteria were enrolled. 
They were grouped into two and underwent either trabeculectomy or trabeculectomy 
with a collagen implant. Ocular parameters like Visual Acuity, intra-ocular pressure, 
C:D ratio of the ONH, Loss Variance by AP and RNFL thickness by OCT were 
monitored in the follow-up period. 
 
Statistical comparison of the results was performed both within the groups and 
between the groups to find out the significance of changes in the ocular parameters.  
In our study, 31 patients (81%) were above the age of 40. They were equally 
distributed between the groups. 5 patients with juvenile glaucoma were also enrolled 
as surgery was required in view of advanced glaucomatous damage. 
 
Males and Females were equally distributed in the trabeculectomy group (50% 
each). In the group which had the OloGen implant, 65% were males and 35% were 
females. However, the Chi square test did not show any significant difference 
between the groups (p value of 0.62). 
 
Most patients included in the study (35 out of 39 patients) had an uncontrolled 
IOP of >21 mm of Hg in spite of medical therapy. 10% of patients needed surgery 
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though they had IOP in the range of 16 to 20 mm of Hg as the ONH damage and field 
loss was advanced. 
 
The central corneal thickness was between 501 and 600 microns in 81% of 
patients. For all patients, CCT corrected IOP was taken into consideration for the 
purpose of statistical analysis. 
 
Automated perimetry analysis of the visual fields and OCT for the RNFL 
thickness was done on all patients. Some patients could not perform these tests owing 
to poor vision due to the disease process.  
 
The ONH C:D ratio was estimated using the direct ophthalmoscope and it was 
seen that a majority of those needing surgery had advanced glaucomatous cupping 
(30% patients in the trabeculectomy group and 32% in the trabeculectomy with 
OloGen group).  
 
One patient for whom trabeculectomy with the OloGen implant was 
performed in both eyes was lost to follow-up after the 3rd month of surgery. This 
patient was excluded from further analysis. 
 
After trabeculectomy, the mean drop in IOP of 8.61 mm of Hg was observed 
at the end of a two year follow up. This was statistically significant with a p value of 
<0.001. The cup: disc ratio was also significantly different with a p value of 0.016. 
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Despite improvement in the above parameters, the drop in RNFL thickness was 
significant with a p value of 0.05. Measurement of LV did not show any significant 
difference.  
 
In contrast, the group which underwent trabeculectomy with a collagen 
implant did not show any significant difference in the C:D ratio, LV by AP nor RNFL 
thickness. However, the IOP showed a significant drop of 12.96 mm of Hg. Analysis 
revealed a p value of <0.001 for the drop in IOP. 
 
Comparing the outcomes of surgery in the two groups, there was a mean 
difference of 5.01 mm of Hg at the first week. This showed a significantly higher IOP 
in the implant group (p value of 0.020). this was attributed to the mechanical effect of 
the implant and its hygroscopic swelling in the sub-conjunctival region. The process 
of implant degradation and integration takes a period of around 6 months. Thereafter, 
the IOP at 1 year and 2 years had a mean difference of 3.42 and 4.38 respectively. 
This showed a significant drop of IOP in the collagen implant group (p values of 
0.019 and 0.001 respectively). 
 
Subsequent comparisons of the C:D ratio, loss variance and the RNFL 
thickness between the two groups did not show any difference either before surgery or 
at any stage of follow-up 
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In our study, though visual acuity did change, the effect of surgery on this 
parameter did not show any difference between the two groups as can be seen from 
the p value of 0.83 derived by the Chi square test. 
 
Grading of the blebs by the Moorefields Bleb Grading System (MBGS) 
showed that when compared to the trabeculectomy group which had flat blebs, those 
in the trabeculectomy with OloGen group had larger and more diffuse blebs. In terms 
of bleb and conjunctival vascularisation, both groups were similar. 
 
Applying the criteria for success, 45% of eyes (9 eyes) in the trabeculectomy 
group and 65% of eyes (11 eyes) in the trabeculectomy with collagen implant group 
were deemed to have attained complete success. Addition of topical agents or re-
surgery enabled 25% of eyes in the trabeculectomy group and 17.6% of eyes in the 
trabeculectomy with collagen implant group to qualify as having had a successful 
outcome. 
 
On looking into the complications encountered in the trabeculectomy with 
collagen implant group, allergic reactions were most common (23.5% of eyes). Two 
large overhanging blebs and 3 encysted blebs were also seen. 
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CONCLUSION 
Trabeculectomy has traditionally been considered the gold standard surgery 
for glaucoma. Any new modality is always compared to trabeculectomy in terms of 
efficacy and complications. In spite of the coveted status it enjoys, trabeculectomy has 
its own limitations. Most surgeons find that trabeculectomy tends to fail over a course 
of time. This is primarily because of scarring of the bleb and the adjacent conjunctiva. 
The novel bio-integrable collagen implant regulates the process of bleb formation. It 
provides a framework for orderly deposition of collagen and hence ensures minimal 
scarring and bleb disorganization. 
 
In our study, we have described and compared the results of trabeculectomy 
surgery performed on 20 patients and trabeculectomy surgery with Ologen implant 
performed on 19 patients. At the end of a two year follow-up, though the drop in IOP 
in both groups was significant, sustained low levels were achieved more often in 
patients who had the collagen implant. Moreover, other ocular parameters suggestive 
of glaucoma progression like increase in the loss variance on automated perimetry or 
thinning of the retinal nerve fiber layer were not encountered.  
 
Bleb morphology tends to be favourably altered with the use of the implant as 
can be seen with use of the Moorefields bleb grading system. At the end of a two year 
follow up period, more number of eyes in the implant group maintained the complete 
80 
 
success of surgery. Some patients showed adverse reactions to the implant. 
Nevertheless, serious complications like bleb leak and blebitis were not seen.  
 
The collagen implant can hence be use as a safe additive to the trabeculectomy 
surgery since it enhances the results of the procedure without any serious ocular 
effects directly attributable to the implant. As all steps of surgery are essentially the 
same as trabeculectomy, surgeons can carry out the procedure confidently to better 
the outcomes of their surgery in the long run. 
 
FUTURE SCOPE 
 
Our study comparing the surgical outcomes of trabeculectomy with and 
without the OloGen implant has showed that the collagen implant does play a positive 
role in maintaining the bleb architecture for the follow-up period of two years. 
However, since it is believed that the main advantage of using the collagen implant is 
the bleb maintenance for a long term, we need a longer follow-up to provide 
conclusive evidence of its efficacy. Studies that compare the results of trabeculectomy 
with collagen implants and antimetabolites could shed more light into the domain of 
long term maintenance of bleb architecture since both of them act as wound 
modulants albeit in different mechanisms. 
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TRABECULECTOMY WITH COLLAGEN IMPLANT GROUP 
 
S. 
NO 
NAME  AGE SEX  DIAGNOSIS  EYE 
AT PRESENTATION 
SURGERY
1ST WEEK  1ST MONTH  3RD MONTH  6TH MONTH   1ST YEAR  2ND YEAR 
REMARKS 
VA  IOP  CT  CD  GONIO  AP LV RNFL  VA  IOP C:D VA  IOP C:D VA  IOP C:D VA  IOP  C:D  GONIO   LV OCT VA  IOP C:D GONIO   LV  OCT VA  IOP C:D GONIO   LV OCT
1  GOVINDANAIDU  62  M  BE POAG  RE  PL  26  555  0.9  II/II/II/I  _  83 
RE AG 
& O 
PL  24 0.9 PL  22 0.9 PL  20 0.9 PL  20  0.9  II/II/II/II  _  85  PL  19 0.9 II/II/II/II  _  85  PL  20  0.9 II/II/II/II  _  87 
 
2  MOHAN  29  M  BE POAG  LE 
1/60 
NIP 
16  573  0.9  III/III/III/III _  ‐ 
LE AG 
& O 
5/60 
NIP 
32 0.9
6/60 
NIP 
25 0.9
6/60 
NIP 
24 0.9
6/60 
NIP 
20  0.9  III/III/III/III _  ‐ 
6/60 
NIP 
22 0.9 III/III/III/III _  ‐ 
6/60 
NIP 
22  0.9 III/III/III/III _  _  MMT 
3  S.MUTHU  57  M  BE POAG  RE 
6/9 
PH 
6/6 
34  536  0.9  II/II/II/II  43.3 77 
RE AG 
& O 
6/12 
PH 
6/9 
18 0.9
6/12 
PH 
6/9 
17 0.9
6/12 
PH 
6/9 
16 0.9
6/12 PH 
6/9 
19  0.9  II/II/II/II  54  76 
6/12 
PH 
6/9 
20 0.9 II/II/II/II  39.4  75 
6/9 PH 
6/6 
20  0.9 II/II/II/II  27  74 
MT, 
 MTF 
4  SETHURAMAN  59  M  BE PACG  RE 
6/36 
PH 
6/18 
32  512  0.7  II/II/II/III  12.2 126
RE AG 
& O 
6/60 
NIP 
30 0.7
6/36 
PH 
6/18
26 0.7
6/36 
PH 
6/18
24 0.7
6/36 PH 
6/18 
20  0.7  II/II/II/III  13  128
6/36 
PH 
6/18 
16 0.7 II/II/II/III  14.4  129
6/24 
PH 
6/12 
16  0.7 II/II/II/III  15  132
 
5  RAMANI  59  M  BE PACG  RE 
6/60 
PH 
6/36 
36  519  0.5  I/I/I/CL  14.7 121
RE AG 
& O 
6/60 
NIP 
26 0.5
6/60 
NIP 
24 0.5
6/60 
PH 
6/36
20 0.5
6/60 PH 
6/36 
19  0.5  I/I/I/CL  4.4 123
6/60 
PH 
6/36 
18 0.5 I/I/I/CL  6.6  119
6/60 
PH 
6/36 
18  0.5 I/I/I/CL  7.5 121
 
6  SWAMINATHAN  51  M  BE POAG  LE 
6/36 
PH 
6/24P 
42  578  0.7  III/III/II/III 12.2 108
LE AG 
& O 
6/36 
P NIP
30 0.7
6/36 
PH 
6/24P
32 0.7
6/36 
PH 
6/18P
32 0.7
6/36 PH 
6/18P 
26  0.7  III/III/II/III 13  106
6/36 
PH 
6/18P
21 0.7 III/III/II/III 8.6  105
6/36 
PH 
6/24P
19  0.7 III/III/II/III 7.2 106
 
7  GOVINDHASWAMY  63  M  RE PACG  RE 
6/24 
PH 
6/18P 
23  522  0.8  CL/CL/I/I 35.3 135
RE AG 
& O 
6/60 
PH 
6/36P
17 0.8
6/60 
PH 
6/36P
18 0.8
6/36 
PH 
6/18
16 0.8
6/36 PH 
6/18 
18  0.8  CL/CL/I/I 28  132
6/36 
PH 
6/18 
18 0.8 CL/CL/I/I 15.7  126
6/36 
PH 
6/24 
16  0.8 CL/CL/I/I 9.8 128
 
8  MADHAN MOHAN  34  M  BE PACG  RE 
6/18P 
NIP 
46  581  0.4  CL/I/CL/I 6.9  114
RE AG 
& O 
6/24P 
PH 
6/24
34 0.4
6/18P 
NIP 
26 0.4
6/18 
PH 
6/9 
22 0.4
6/18 PH 
6/9 
16  0.4  CL/I/CL/I 8.9 112
6/18 
PH 
6/9 
17 0.4 CL/I/CL/I 20.8  110
6/18 
PH 6/9
23  0.5 CL/I/CL/I 17  113
MT, 
RE TR 
9  KAVITHA  43  F  BE POAG  LE 
6/12 
PH 
6/9 
28  487  0.8  II/II/III/II  37.7 93 
LE AG 
& O 
6/18 
NIP 
24 0.8
6/18 
NIP 
20 0.8
6/18 
PH 
6/12P
17 0.8
6/18 PH 
6/12P 
14  0.8  II/II/III/II  22  94 
6/18 
PH 
6/12P
15 0.8 II/II/III/II  18  95 
6/18 
PH 
6/12P
14  0.8 II/II/III/II  26  94 
 
10  RAJESHWARI  68  F  BE PACG  RE 
6/24 
PH 
6/12 
25  503  0.6  I/I/I/CL  7.3  127
RE AG 
& O 
6/36P 
PH 
6/18
26 0.6
6/36 
NIP 
2  0.6
6/36 
PH 
6/24
18 0.6
6/36 PH 
6/24 
22  0.6  I/I/I/CL  8.8 128
6/36 
PH 
6/24 
20 0.6 I/I/I/CL  10.4  124
6/36 
PH 
6/24 
21  0.7 I/I/I/CL  6.8 124
 
11  RASIYA  49  F  BE PACG  LE 
6/12 
NIP 
24  501  0.9  CL/CL/I/II 21.5 112
LE AG 
& O 
6/24 
PH 
6/12
22 0.9
6/18 
PH 
6/9 
18 0.9
6/18 
PH 
6/9 
12 0.9
6/18 PH 
6/9 
16  0.9  CL/CL/I/II 23  110
6/18 
PH 
6/9 
16 0.9 CL/CL/I/II 34.6  116
6/18 
PH 6/9
18  0.9 CL/CL/I/II 29  112
 
12  NAYAGAM  55  F  BE PACG  LE 
6/9 
PH 
6/6 
20  560  0.9  CL/CL/CL/I 85.1 95 
LE AG 
& O 
2/60 
NIP 
16 0.9
3/60 
NIP 
16 0.9
6/24 
PH 
6/18
14 0.9
6/24 PH 
6/18 
14  0.9  CL/CL/CL/I 44  94 
6/18 
PH 
6/9 
15 0.9 CL/CL/I/I 54  94 
6/12 
PH 
6/6P 
12  0.9 CL/CL/I/I 48  95 
 
13  FRANCIS  42  M  RE JG  RE 
6/12 
PH 
6/9 
32  500  0.7  III/IV/IV/III 15.6 100
RE AG 
& O 
6/24 
NIP 
27 0.7
6/24 
PH 
6/18
29 0.7
6/24 
PH 
6/12
16 0.7
6/24 PH 
6/12 
12  0.7  II/III/III/II 7.2 106
6/24 
PH 
6/12 
10 0.7 II/III/III/II 8.1  104
6/12 
PH 
6/6P 
14  0.7 II/III/III/II 8.4 104
MT, 
REV 
14  SUMATHY  33  F  BE PACG  RE 
6/18 
PH 
6/12P 
40  507  0.8  II/I/I/I  24.6 ‐ 
RE AG 
& O 
6/18 
PH 
6/9 
28 0.8
6/18 
PH 
6/6 
28 0.8
6/18 
PH 
6/9 
16 0.9
6/12 PH 
6/6 
13  0.9  II/I/I/I  13  ‐ 
6/9 
PH 
6/6 
14 0.9 II/I/I/I  16.5  ‐ 
6/12 
PH 6/6
16  0.9 II/II/I/I  7.7 ‐ 
MT, 
MTF 
15  JAMUNA  48  F  BE POAG  LE 
6/60 
PH 
6/24P 
30  505  0.8  II/III/III/III 35.2 79 
LE AG 
& O 
6/12 
PH 
6/9 
14 0.8
6/24 
PH 
6/18
13 0.8
6/12 
PH 
6/9 
12 0.8
6/12 PH 
6/9 
15  0.8  II/III/II/III 12  75 
6/12 
PH 
6/9 
14 0.8 II/III/II/III 16.2  79 
6/12 
NIP 
12  0.8 II/II/II/III  6.9 82 
 
16  JAMUNA  48  F  BE POAG  RE 
6/12 
PH 
6/9 
25  510  0.8  III/III/III/III 44.9 77 
RE AG 
& O 
6/18 
PH 
6/6 
12 0.8
6/9P 
NIP 
14 0.8
6/9P 
NIP 
14 0.8
6/9P 
NIP 
12  0.8  III/III/III/III 26  82 
6/9P 
PH 
6/6P 
16 0.8 III/II/II/II  22.2  82 
6/9P 
PH 
6/6P 
14  0.8 III/II/II/II  16  86 
 
17  GOWRI  38  F  BE CG  LE 
6/36 
PH 
6/18 
26  534  0.9  III/III/III/III 8.1  ‐ 
LE AG 
& O 
6/60 
PH 
6/36
28 0.9
6/60 
PH 
6/24P
35 0.9
6/36P 
PH 
6/24
38 0.9
6/36 PH 
6/18 
26  0.9  III/III/III/III 9.3 ‐ 
6/36 
PH 
6/18 
21 0.9 III/III/II/II 14.5  ‐ 
6/36 
PH 
6/18 
21  0.9 III/III/II/II 10  _  MMT 
18  TAMILARASAN  14  M  BE CG  RE  
6/60 
NIP 
24  610  0.5  II/II/II/II  _  ‐ 
RE AG 
& O 
6/60 
NIP 
26 0.5
6/60 
PH 
6/36P
18 0.5
6/36P 
NIP 
20 0.5 _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _ 
LOST TO  
FOLLOW UP 
19  TAMILARASAN  14  M  BE CG  LE 
6/60 
PH 
6/36 
34  625  0.8  II/II/II/I  _  ‐ 
LE AG 
& O 
6/60 
NIP 
28 0.8
6/36 
PH 
6/24
16 0.8
6/36 
PH 
6/24P
18 0.8 _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _ 
LOST TO  
FOLLOW UP 
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TRABECULECTOMY GROUP 
S. 
NO 
NAME  AGE SEX  DIAGNOSIS  EYE 
AT PRESENTATION 
SURGERY
1ST WEEK  1ST MONTH  3RD MONTH  6TH MONTH   1ST YEAR  2ND YEAR 
REMARKS 
VA  IOP  CT  CD  GONIO  LV  RNFL  VA  IOP C:D VA  IOP C:D VA  IOP C:D VA  IOP  C:D  GONIO   LV OCT VA  IOP C:D GONIO   LV  OCT VA  IOP C:D GONIO   LV OCT
1  RAMALINGAM  60  M  BE PACG  LE 
2/60 
NIP 
48  510  0.8  I/I/I/I  _  78  LE AG 
1/60 
NIP 
22 0.8
2/60 
NIP 
16 0.8
2/60 
NIP 
25 0.8
2/60 
NIP 
28  0.9  I/CL/I/I  _  75 
2/60 
NIP 
28 0.9 I/CL/I/I  _  72 
2/60 
NIP 
30  0.9 I/I/I/I  _  72  MMT 
2  RAVI  55  M  BE PACG  LE 
6/36 
PH 
6/9 
37  578  0.4  CL/CL/I/I 7.7  112 LE AG  
6/60 
NIP 
36 0.4
6/60 
NIP 
20 0.4
6/60 
NIP 
18 0.4 6/36NIP 18  0.4  CL/CL/I/I 11  110
6/36 
NIP 
18 0.4 CL/CL/I/I 13.4  105
6/36 
PH 
6/24 
18  0.5 CL/I/I/I  24  100
 
3  VIJAYAKUMAR  32  M  BE POAG  RE 
6/60 
NIP 
38  532  0.9  II/II/IV/II  _  83  RE AG 
4/60 
NIP 
18 0.9
6/60 
NIP 
20 0.9
6/60 
NIP 
22 0.9
6/60 
NIP 
21  0.9  II/II/II/II  _  84 
6/60 
NIP 
22 0.9 II/II/II/II  _  80 
6/60 
NIP 
17  0.9 II/II/II/II  _  79 
MT, 
RE TR 
4  KAMALA  62  F  BE POAG  LE 
6/36 
PH 
6/12 
25  502  0.8  III/III/III/III 27.6 108 LE AG  
5/60 
PH 
6/60
15 0.8
6/36 
PH 
6/12
18 0.8
6/36 
PH 
6/12
20 0.8
6/36 PH 
6/12 
18  0.8  III/III/III/III 21  110
6/36 
PH 
6/12 
20 0.8 III/III/III/III 16.2  105
6/36 
PH 
6/12 
21  0.8 III/III/III/III 30  105
 
5  KAMALA  62  F  BE POAG  RE 
6/18 
PH 
6/12 
27  505  0.9  III/II/III/II 8.9  114 RE AG 
6/36 
NIP 
22 0.9
6/36 
NIP 
20 0.9
6/36 
PH 
6/24P
17 0.9
6/36 PH 
6/18 
16  0.9  III/II/III/II 17  116
6/36 
PH 
6/18 
17 0.9 III/II/III/II 11.1  113
6/36 
NIP 
21  0.9 III/II/II/II  9.7 111
 
6  SUSEELA  67  F  BE PACG  LE 
6/36 
NIP 
42  536  O.5  CL/I/CL/I 6.5  119 LE AG  
2/60 
NIP 
16 0.5
3/60 
NIP 
17 0.5
6/60 
NIP 
14 0.5
6/60 
NIP 
6/36 
16  0.5  CL/I/CL/I 5.1 120
6/60 
PH 
6/36 
18 0.5 CL/I//CL/I/ 7.5  118
6/36 
NIP 
19  0.5 CL/I/CL/I 10  118
 
7  MANI  54  M  RE POAG  RE 
6/36P 
PH 
6/18 
39  511  0.8  III/III/III/III 81.3 128 RE AG 
6/60P 
NIP 
25 0.8
6/60 
NIP 
22 0.8
6/60 
PH 
6/36
20 0.8
6/60 PH 
6/36 
22  0.8  III/III/III/III 65  126
6/60 
NIP 
20 0.8 II/III/III/II 60.4  124
6/60 
NIP 
20  0.8 II/III/III/II 49  125 MT 
8  RAMALINGAM  57  M  BE PACG  RE 
6/36 
PH 
6/18P 
34  571  0.9  I/I/I/I  29.8 103 RE AG 
6/36 
NIP 
15 0.9
6/36 
NIP 
17 0.9
6/36 
PH 
6/18
17 0.9
6/36 PH 
6/18 
18  0.9  I/I/I/I  12  ‐ 
6/36 
NIP 
19 0.9 I/I/I/I  15.2  99 
6/36 
NIP 
18  0.9 I/I/I/I  18  97 
 
9  RAMALINGAM  57  M  BE PACG  LE 
6/60 
PH 
6/24P 
28  559  0.9  CL/I/I/CL 19.9 116 LE AG  
6/60 
PH 
6/36
13 0.9
6/60 
PH 
6/36
13 0.9
6/36 
NIP 
14 0.9
6/36 P 
PH 6/24
14  0.9  CL/I/I/CL 11  113
6/36 
PH 
6/24 
16 0.9 CL/I/I/CL 6.5  114
6/36 
NIP 
16  0.9 CL/CL/CL/I 8.2 109
 
10  APARUPAM  47  F  BE POAG  RE 
6/12 
PH 
6/9 
20  496  0.7  II/II/II/I  26.4 117 RE AG 
6/36 
PH 
6/24
12 0.7
6/36 
NIP 
12 0.7
6/24 
PH 
6/9P
14 0.7
6/12 
NIP 
14  0.7  II/II/II/II  18  115
6/12 
NIP 
12 0.7 II/II/II/I  12.6  115
6/12 
PH 6/9
12  0.7 II/II/II/II  20  114
 
11  THANGAVEL  69  M  BE POAG`  RE  
6/24 
PH 
6/12 
26  525  0.8  II/II/III/II  18.2 109 RE AG 
6/24 
NIP 
18 0.8
6/24 
PH 
6/9 
17 0.8
6/24 
PH 
6/9 
15 0.8
6/24 PH 
6/9 
24  0.8  II/II/III/II  7.4 110
6/24 
PH 
6/9 
22 0.8 II/II/III/II  8.5  107
6/24 
PH 6/9
23  0.8 II/I/III/Ii  15  106 MMT 
12  KASTHURI  57  F  BE POAG  LE 
6/9 
PH 
6/6 
16  550  0.6  III/II/III/II 5.3  85  LE AG 
6/24 
PH 
6/18P
10 0.6
6/24 
PH 
6/9 
12 0.6
6/9 
NIP 
12 0.6
6/9 PH 
6/6 
23  0.7  III/II/III/II 8.1 85 
6/9 
PH 
6/6 
13 0.7 III/II/II/III 6.2  82 
6/9 PH 
6/6 
14  0.6 III/III/II/II 5.6 86 
MT, 
RE TR 
13  KATHISHA BEEVI  55  F  BE PACG  RE  
3/60 
NIP 
22  587  0.9  I/I/CL/I  39.1 ‐  RE AG 
3/60 
NIP 
17 0.9
3/60 
NIP 
18 0.9
3/60 
NIP 
16 0.9
3/60 
NIP 
17  0.9  I/I/CL/I  21  _ 
5/60 
NIP 
22 0.9 I/I/CL/I  20.6  _ 
6/60 
NIP 
24  0.9 I/I/CL/I  23  _ 
MT, 
RE TR 
14  AROKIANATHAN  54  M  BE PACG  RE 
6/18 
NIP 
21  605  0.8  CL/CL/I/CL 8.2  76  RE AG 
6/24 
PH 
6/18
12 0.8
6/36 
PH 
6/24
13 0.8
6/36 
PH 
6/24P
13 0.8
6/18 PH 
6/12 
20  0.8  CL/CL/CL/I 4.2 74 
6/18 
NIP 
24 0.8 CL/CL/I/CL 5.8  79 
6/18 
PH 6/9
26  0.8 CL/CL/I/CL 7.5 82 
MT, 
RE TR 
15  MALA  58  F  BE PACG  RE 
6/60 
PH 
6/36 
27  534  0.5  CL/CL/I/I 7.1  89  RE AG 
6/36 
NIP 
18 0.5
6/60 
PH 
6/36
18 0.5
6/60 
PH 
6/36
25 0.5
6/60 PH 
6/36 
25  0.5  CL/CL/I/I 11  89 
6/60 
PH 
6/36 
26 0.5 CL/CL/CI/I 13.2  96 
6/36 
PH 
6/24 
24  0.6 CL/CL/I/I 12  97  MMT 
16  VASANTHAKUMARI  48  F  BE PACG  LE 
6/18 
PH 
6/6 
24  570  0.8  I/CL/II/CL 43.7 125 LE AG  
6/24 
PH 
6/18
20 0.8
6/18 
PH 
6/6 
19 0.8
6/18 
PH 
6/6 
21 0.8
6/18 PH 
6/6 
20  0.8  I/CL/II/CL 37  126
6/18 
PH 
6/6 
20 0.8 I/CL/II/CL 19.6  125
6/18 
PH 6/6
21  0.8 I/CL/II/CL 14  128
MT, 
MTF 
17  VANI  55  F  BE POAG  RE 
6/24 
PH 
6/12 
25  564  0.9  II/II/II/II  33.8 86  RE AG 
6/36 
PH 
6/24P
14 0.9
6/24 
PH 
6/12
14 0.9
6/24 
PH 
6/12
16 0.9
6/24 PH 
6/12 
16  0.9  II/II/II/II  46  84 
6/18P 
NIP 
19 0.9 II/II/III/II  32.3  83 
6/18P 
NIP 
20  0.9 II/II/II/II  28  83 
 
18  PARASARURAMAN  49  M  BE POAG`  RE  
4/60 
NIP 
34  497  0.7  III/III/IV/III _  120 RE AG 
3/60 
NIP 
30 0.7
6/60 
NIP 
26 0.7
6/60 
NIP 
22 0.7
6/60 
NIP 
20  0.7  III/III/IV/III _  118
6/60 
NIP 
20 0.7 III/III/III/III _  120
6/60 
NIP 
21  0.7 III/III/III/III _  126 MT 
19  MADHAVAN  26  M 
RE JUVENILE 
GLAUCOMA 
RE 
6/24 
PH 
6/18 
32  564  0.8  III/II/III/II 21.2 78  RE AG 
6/24 
PH 
6/18P
16 0.8
6/24 
PH 
6/18P
16 0.8
6/24 
PH 
6/18P
18 0.8
6/24 PH 
6/18P 
20  0.8  III/II/III/II 14  82 
6/24 
PH 
6/18P
20 0.8 III/II/II/III 16.5  82 
6/12 
NIP 
20  0.8 III/III/II/II 23  83 
 
20  JEYASUDHA  12  F 
BE 
CONGENITAL 
GLAUCOMA 
LE 
6/60 
NIP 
28  597  0.7  III/III/IV/III _  118 LE AG 
3/60 
NIP 
15 0.7
4/60 
NIP 
15 0.7
3/60 
NIP 
25 0.7
4/60 PH 
6/60 
22  0.7  III/III/IV/III _  115
4/60 
PH 
6/60 
22 0.7 III/IV/III/IV _  110
6/60 
PH 
6/36 
22  0.8 III/III/IV/III _  116 MMT 
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